Colorectal Cancer Screening Programme in Spain: Results of Key Performance Indicators after Five Rounds (2000-2012)

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Binefa, Gemma ^a,b,c   Garcia, Montse ^a   Mila, Nuria ^a,b   Fernandez, Esteve ^a,c   Rodriguez Moranta, Francisco ^b,d   Gonzalo, Nuria ^a   Benito, Llucia ^a,c   Clopes, Ana ^a   Guardiola, Jordi ^d   Moreno, Victor ^a,b,c  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; HEALTH CARE QUALITY; HEALTH SURVEY; HUMAN; MASS SCREENING; MIDDLE AGED; PROCEDURES; REPRODUCIBILITY; SPAIN;

ADULT; AGED; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; HUMANS; MASS SCREENING; MIDDLE AGED; POPULATION SURVEILLANCE; QUALITY INDICATORS, HEALTH CARE; REPRODUCIBILITY OF RESULTS; SPAIN;

EID: 84955309255     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19532     Document Type: Article

References (48)

1. Arbin, M. et al. European Commission's proposal for a council recommendation on cancer screening. B.M. J 327, 289-290 (2003).
2. Felix Burda Foundation. Europe against colorectal cancer. Declaration of Brussels, 9 may 2007. Available at: http://www.futurehealth-2007.com. (Accessed: December 2014).
3. Von Karsa, L. et al. Cancer screening in the European Union. Report on the implementation of the Council Recommendation on Cancer Screening. (International Agency for Research of Cancer, European Communities, 2008).
4. Hewitson, P., Glasziou, P., Watson, E., Towler, B., Irwig, L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am. J. Gastroenterol. 103, 1541-1549 (2008).
5. Benson, V. S. et al. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int. J. Cancer. 122, 1357-1367 (2008).
6. Rabeneck, L. et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can. J. Gastroenterol. 26, 131-147 (2012).
7. Barrett, B., McKenna, P. Communicating benefits and risks of screening for prostate, colon, and breast cancer. Fam. Med. 43, 248-253 (2011).
8. Dreier, M. et al. Communicating the benefits and harms of colorectal cancer screening needed for an informed choice: a systematic evaluation of leaflets and booklets. PLoS. One. 9, e107575 (2014).
9. Segnan, N. European guidelines for quality assurance in colorectal cancer screening and diagnosis. 1st ed. (eds. Patnick, J., von Karsa, L.) (European Commission, Publications Office of the European Union, 2010).
10. Ascunce, N. et al. Cancer Screening in Spain. Ann. Oncol. 21, iii43-iii51 (2010).
11. Cancer Screening Programmes Network. Situation of Colorectal Cancer Screening programmes in Spain. Available at: http://www. cribadocancer.org. (Accessed: 24th October 2015).
12. Peris, M. et al. Lessons learnt from a population-based pilot program for colorectal cancer screening in Catalonia (Spain). J. Med. Screen. 14, 81-86 (2007).
13. Statistical Institute of Catalonia. Idescat. Available at: www.idescat.cat. (Accessed: 20th January 20, 2015).
14. Catalan Health Service. Central Registry of Insured. Available at: http://catsalut.gencat.cat/ca/proveidors-professionals/registrescatalegs/registres/centre-assegurats/(Accessed: 29th October 2015).
15. Jass, J. R. Histological typing of intestinal tumors 2nd edn (ed. Sobin, L. H.) (Springer-Verlag, 1989).
16. Sobin, L. H. TNM classification of malignant tumours 6th edn. (ed. Wittekind, Ch.) (International Union Against Cancer, 2002).
17. Grup de treball sobre cribratge de cáncer de còlon i recte. Proposta de criteris generals d'organització i funcionament del programa de detecció precoc de cáncer de colon i recte de Catalunya 1st edn (Comissió Assesora de Cribratge de Càncer, 2010).
18. Moss, S. M. et al. Performance measures in three rounds of the English bowel cancer screening pilot. Gut. 61, 101-107 (2012).
19. Steele, R. J. C. et al. Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut. 58, 530-535. (2009).
20. Faivre, J. et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 80, 1674-1680 (2004).
21. Málaga, A. et al. Programme of screening for colorrectal cancer in the Valencia community, Spain: results of the first round (2005-2008). Rev. Esp. Salud Pública. 84, 731-743 (2010).
22. Portillo, I. et al. Main results of the colorectal cancer screening program in the Basque Country (Spain). Gac. Sanit. 27, 358-361 (2013).
23. Burón, A. et al. Colorectal Cancer Early Screening Program of Barcelona: Indicators of the first round of a program with participation of community pharmacies. Med. Clin. 7753, 412-416 (2014).
24. Guittet, L., Bailly, L., Bouvier, V., Launoym, G. Indirect comparison of two quantitative immunochemical faecal occult blood tests in a population with average colorectal cancer risk. J. Med. Screen. 18, 76-81(2011).
25. Levi, Z. et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int. J. Cancer. 128, 2415-2424 (2011).
26. Berchi, C., Guittet, L., Bouvier, V., Launoy, G. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening. Int. J. Technol. Assess. Health Care. 26, 48-53 (2010).
27. Guittet, L. et al. Analytical comparison of three quantitative immunochemical fecal occult blood tests for colorectal cancer screening. Cancer Epidemiol. Biomarkers Prev. 20, 1492-1501 (2011).
28. van Roon, A. H. et al. Are fecal immunochemical test characteristics influenced by sample return time A population-based colorectal cancer screening trial. Am. J. Gastroenterol. 107, 99-107 (2012).
29. Grazzini, G. et al. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut. 59, 1511-1515 (2010).
30. Grazzini, G. et al. Colorectal cancer screening programme by faecal occult blood test in Tuscany: first round results. Eur. J. Cancer Prev. 13, 19-26 (2004).
31. Rex, D. K. et al. Quality indicators for colonoscopy. Am. J Gastroenterol. 101, 873-885 (2006).
32. Binefa, G. et al. Colonoscopy quality assessment in a mass population screening program based on fecal occult blood test. Rev. Esp. Enf. Dig. 105, 400-408 (2013).
33. Lee, T. J. W. et al. Colonoscopy quality measures: experience from the NHS Bowel Cancer Screening Programme. Gut. 61, 1050-1057 (2012).
34. Morán, S. et al. Colonoscopy quality assessment. Rev. Esp. Enferm. Dig. 101, 107-112 (2009).
35. Lieberman, D. et al. Standardized colonoscopy reporting and data system (CO-RADS): Report of Quality Assurance Task Force Group of the National Colorectal Cancer Roundtable. Gastrointestinal Endoscopy. 65, 757-766 (2007).
36. Garcia, M. et al. False-positive results from colorectal cancer screening in Catalonia (Spain), 2000-2010. J. Med. Screen. 19, 77-82 (2012).
37. van Turenhout, S. T. et al. Hemorrhoids detected at colonoscopy: an infrequent cause of false-positive fecal immunochemical test results. Gastrointest. Endosc. 76, 136-143 (2012).
38. Kahi, C. J., Imperiale, T. F. Do aspirin and nonsteroidal anti-inflammatory drugs cause false-positive fecal occult blood test results A prospective study in a cohort of veterans. Am. J. Med. 117, 837-841 (2004).
39. Levi, Z. et al. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol. 104, 933-938 (2009).
40. Sawhney, M. S., McDougall, H., Nelson, D. B., Bond, J. H. Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci. 55, 1637-1642 (2010).
41. Park, D. I. et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am. J. Gastroentero. 105, 2017-2025 (2010).
42. Hol, L. et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 59, 62-68 (2010).
43. Haug, U., Hundt, S., Brenner, H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am. J. Gastroenterol. 105, 682-690 (2010).
44. Guittet, L. et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut. 56, 210-214 (2007).
45. Steele, R. J. et al. Effect of repeated invitations on uptake of colorectal cancer screening using faecal occult blood testing: analysis of prevalence and incidence screening. B.M.J. 341, c5531 (2010).
46. Kaminski, M. F. et al. Quality indicators for colonoscopy and the risk of interval cancer. N. Engl. J. Med. 362, 1795-1803 (2010).
47. Bressler, B. et al. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology. 132, 96-102 (2007).
48. Garcia, M. et al. Factors associated with initial participation in a population-based screening for colorectal cancer in Catalonia, Spain: a mixed-methods study. Prev. Med. 52, 265-267 (2011